UCB today announced that the company has regained all global rights to bepranemab following termination of a collaboration ...

Regenxbio and AbbVie announced positive Phase II results for gene therapy ABBV-RGX-314 in wet AMD, showing a 97% reduction in ...

ICER has released its final report on treatments for transthyretin amyloid cardiomyopathy, evaluating Pfizer’s Vyndamax, ...

Japanese clinical-stage biotech Aculys Pharma announced that pitolisant (BF2.649), a histamine H3 receptor antagonist/inverse ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg ...

Berlin, Germany-based Ariceum Therapeutics presented promising preclinical data at EANM 2024 on its radiop5Ac-satoreotide for ...

Philadelphia-based SERB Pharmaceuticals has acquired Aurlumyn, the only FDA-approved treatment for severe frostbite in the ...

Melbourne, Australia-based Telix Pharmaceuticals has launched Rhine Pharma, a subsidiary focused on enhancing global access ...

Otsuka Pharmaceutical (TYO: 4578) today announced positive top-line interim data from the ongoing Phase III clinical trial of ...

Tremfya (guselkumab) demonstrated strong results in the Phase III GRAVITI trial, marking a major breakthrough in the ...

UK pharma major AstraZeneca’s Alexion Rare Disease unit has received a positive recommendation for Voydeya (danicopan), from ...

Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and ...